Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2014. The report specifically addresses a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) under the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding internal plan transactions rather than a financial results report.
Material Changes
There were no material changes to the company's financial position reported. The only change noted is an increase in the notional allocation of American Depositary Shares (ADSs) within the GSK 401K plan due to a revaluation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investors to Verify
- Transaction Date: The notional allocation increase occurred on June 20, 2014.
- Share Price: The transaction price was $54.54 per ADS.
- Parties Involved: The transaction involved Dr. M. Slaoui (Director/PDMR) and Dr. K. Slaoui (Connected Person).
- Volume: A total of 3 ADSs were added to the notional allocation.
- Plan Details: The transaction relates to the cash element of the notional investment held within the GSK 401K plan.